Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data for Archexin in Patients with Metastatic Pancreatic Cancer Aug 28, 2012
Rexahn Submits an Investigational New Drug Application to the FDA for First-in-Class p68 Helicase Inhibitor, RX-5902 Jul 2, 2012
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anti-Cancer Compound RX-3117 May 30, 2012
Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting Mar 27, 2012
Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117 Mar 13, 2012